Correlation Between Vaxcyte and Merus BV
Can any of the company-specific risk be diversified away by investing in both Vaxcyte and Merus BV at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vaxcyte and Merus BV into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vaxcyte and Merus BV, you can compare the effects of market volatilities on Vaxcyte and Merus BV and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vaxcyte with a short position of Merus BV. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vaxcyte and Merus BV.
Diversification Opportunities for Vaxcyte and Merus BV
Average diversification
The 3 months correlation between Vaxcyte and Merus is 0.18. Overlapping area represents the amount of risk that can be diversified away by holding Vaxcyte and Merus BV in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Merus BV and Vaxcyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vaxcyte are associated (or correlated) with Merus BV. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Merus BV has no effect on the direction of Vaxcyte i.e., Vaxcyte and Merus BV go up and down completely randomly.
Pair Corralation between Vaxcyte and Merus BV
Given the investment horizon of 90 days Vaxcyte is expected to under-perform the Merus BV. In addition to that, Vaxcyte is 1.13 times more volatile than Merus BV. It trades about -0.33 of its total potential returns per unit of risk. Merus BV is currently generating about -0.27 per unit of volatility. If you would invest 5,282 in Merus BV on August 28, 2024 and sell it today you would lose (743.00) from holding Merus BV or give up 14.07% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Vaxcyte vs. Merus BV
Performance |
| Timeline |
| Vaxcyte |
| Merus BV |
Vaxcyte and Merus BV Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Vaxcyte and Merus BV
The main advantage of trading using opposite Vaxcyte and Merus BV positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vaxcyte position performs unexpectedly, Merus BV can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Merus BV will offset losses from the drop in Merus BV's long position.| Vaxcyte vs. Eliem Therapeutics | Vaxcyte vs. HCW Biologics | Vaxcyte vs. Scpharmaceuticals | Vaxcyte vs. Milestone Pharmaceuticals |
| Merus BV vs. Anebulo Pharmaceuticals | Merus BV vs. Adagene | Merus BV vs. Acrivon Therapeutics, Common | Merus BV vs. AnaptysBio |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Complementary Tools
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |